02034nas a2200313   4500008004100000022001400041245010000055210006900155260010600224300001400330490000700344520092600351653002701277653001601304653001701320653001401337653001701351100002401368700002401392700002101416700002201437700002101459700002101480700001901501700002601520700002301546700002501569856012601594       2008                        eng d  a0960-894X00aSynthesis of chimeric tetrapeptide-linked cholic acid derivatives: impending synergistic agents0 aSynthesis of chimeric tetrapeptidelinked cholic acid derivatives  aTHE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLANDbPERGAMON-ELSEVIER SCIENCE LTDcOCT  a5512-55170 v183 a<p>Tetrapeptides derived from glycine and beta-alanine were hooked at the C-3 beta position of the modified cholic acid to realize novel linear tetrapeptide-linked cholic acid derivatives. All the synthesized compounds were tested against a wide variety of microorganisms (Gram-negative bacteria, Gram-positive bacteria and fungi) and their cytotoxicity was evaluated against human embryonic kidney (HEK293) and human mammary adenocarcinoma (MCF-7) cell lines. While relatively inactive by themselves, these compounds interact synergistically with antibiotics such as fluconazole and erythromycin to inhibit growth of fungi and bacteria, respectively, at 1-24 mu g/mL. The synergistic effect shown by our novel compounds is due to their inherent amphiphilicity. The fractional inhibitory concentrations reported are comparable to those reported for Polymyxin B derivatives. (c) 2008 Elsevier Ltd. All rights reserved.</p>10aAntimicrobial activity10aCholic acid10aCytotoxicity10aSynergism10aTetrapeptide1 aBavikar, Sudhir, N.1 aSalunke, Deepak, B.1 aHazra, Braja, G.1 aPore, Vandana, S.1 aDodd, Robert, H.1 aThierry, Josiane1 aShirazi, Fazal1 aDeshpande, Mukund, V.1 aKadreppa, Sreenath1 aChattopadhyay, Samit  uhttps://library.ncl.res.in/content/synthesis-chimeric-tetrapeptide-linked-cholic-acid-derivatives-impending-synergistic-0